Latest News

How Complementary Diagnostic Technologies Are Advancing Antibiotic Stewardship at the Point of Care

Contributed Commentary by Annie Bell, Lumos Diagnostics 

November 19, 2026 | Every respiratory season brings a familiar surge of acute respiratory infections (ARIs) to outpatient care. Flu, respiratory syncytial virus (RSV), COVID-19, and other respiratory infections place significant demands on urgent care clinics and healthcare systems. During peak respiratory season, patients with respiratory symptoms can account for up to 50% of urgent care visits, putting pressure on clinicians to make timely, informed treatment decisions.

One of the greatest challenges is determining when antibiotics are actually needed. Bacterial and non-bacterial causes of respiratory illness can cause very similar symptoms, making them difficult to distinguish based on symptoms and physical examination alone. Yet the consequences of unnecessary antibiotic use extend beyond an individual patient, contributing to antimicrobial resistance (AMR), which remains a significant global health challenge. An estimated 28% of antibiotics prescribed in outpatient settings are considered unnecessary. 

At the center of many antibiotic prescribing decisions is a critical question: Can a bacterial infection be ruled out?

The Diagnostic Gap Behind Antibiotic Decisions

Antibiotic stewardship is a crucial component of effective ARI management. The stakes extend far beyond a single respiratory visit. Antimicrobial resistance is associated with over 4 million deaths globally each year and is estimated to cost US healthcare systems more than 20 billion dollars annually. Even when a respiratory infection is viral and antibiotics provide no clinical benefit, unnecessary antibiotic prescribing can disrupt the normal gut microbiome and expose patients to adverse drug effects such as diarrhea, allergic reactions, and Clostridioides difficile infection. These unintended consequences may lead to additional healthcare encounters, increased costs, and avoidable patient harm. 

Urgent care clinicians must make treatment decisions in busy, fast-paced environments, often with limited time and incomplete diagnostic information. When a patient presents with respiratory symptoms, clinicians need to determine not only what may be causing the illness, but also whether there is evidence of a bacterial infection that warrants antibiotics.

Rapid point-of-care tests for influenza, Group A Streptococcus, and SARS-CoV-2 have become important tools in respiratory care. Positive results can help identify the cause of illness and guide treatment. However, when results are negative, uncertainty may remain. Even broader multiplex PCR panels that test for numerous pathogens cannot always resolve whether a bacterial infection is present or whether antibiotics are appropriate. 

The challenge, then, is not necessarily a lack of testing. It is that identifying specific pathogens and determining whether antibiotics are needed are two related but different clinical questions. 

Bringing Two Complementary Types of Testing Together

We’re seeing a shift at the point of care, where clinicians are increasingly bringing together pathogen testing and host-response testing. The two provide different, but complementary, pieces of information about an infection. 

Pathogen tests identify the specific pathogen(s) that may be responsible for a patient's symptoms. Host-response tests measure how the body's immune system is responding to infection, providing additional information to help clinicians assess the likelihood of bacterial infection and, importantly, identify patients in whom a bacterial infection may be ruled out.

Both perspectives matter. Detecting a pathogen does not always establish whether it is responsible for a patient's symptoms or fully answer the question of whether antibiotics are warranted. Similarly, a negative pathogen test does not necessarily rule out a bacterial infection.

By looking at both the potential cause of illness and how the body is responding, clinicians gain a clearer picture of whether antibiotics may be necessary. This is particularly valuable when traditional pathogen test results are negative or inconclusive. 

Advances in point-of-care host-response testing are making this information more accessible during the clinical visit. For example, some tests use a simple fingerstick blood sample to measure immune-response biomarkers and deliver results within minutes, allowing clinicians to consider host-response information alongside existing respiratory tests. 

The Patient Conversation Is Part of Stewardship

Diagnostic information is only valuable if it helps clinicians make better decisions and communicate those decisions effectively.

Patients arrive at urgent care with different expectations about antibiotics. Some believe antibiotics are the quickest way to feel better, while others prefer to avoid them unless absolutely necessary. These conversations can be challenging, particularly when a patient's expectations do not align with the recommended treatment.

Objective diagnostic information gives clinicians something tangible to share and explain. By showing patients information about potential pathogens and whether a bacterial infection is present, clinicians can better communicate why antibiotics may or may not be appropriate. This can build confidence in treatment recommendations, particularly when the decision is not to prescribe antibiotics. 

A Clearer Path Forward

No single diagnostic test answers every clinical question. Pathogen testing remains essential for identifying infectious agents, while host-response testing provides complementary information to help clinicians assess and rule out the likelihood of bacterial infection.  

Used alongside existing flu, COVID-19, and strep testing, point-of-care host-response testing can provide another important piece of information during the same visit—helping clinicians make more informed antibiotic decisions before a prescription is written.

Antimicrobial resistance is a global challenge, but antibiotic stewardship starts at the point of care, with one informed prescribing decision at a time.

 

Annie Bell has more than 15 years of professional experience in the medical device and in vitro diagnostic industry including direct patient management, medical education and clinical study management. Currently serving as the Sr. Director of Medical Affairs for Lumos Diagnostics, Ms. Bell is a strategic leader with a passion for simplifying challenging diagnostic dilemmas for patients and clinicians. She has expertise in clinical trial scientific methodology and operational oversight including early feasibility studies, usability studies, CLIA Waiver studies, registration trials, and post-market interventional/cost-effectiveness studies. Ms. Bell holds a BS from Pennsylvania State University, a MS from Rush University Chicago, IL, and completed a post-graduate Global Clinical Trial Research Program with Harvard Medical School, Boston MA. Ms. Bell is a Board-certified Neonatal Nurse Practitioner. She can be reached at annie.bell@lumosdiagnostics.com.

Load more comments
comment-avatar